Compounds > p-chloro-o-toluidine hydrochloride
Page last updated: 2024-12-06

p-chloro-o-toluidine hydrochloride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

p-chloro-o-toluidine hydrochloride: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID18487
CHEMBL ID3182298
SCHEMBL ID131186
MeSH IDM0555395

Synonyms (86)

Synonym
azogene fast red tr
4-chloro-o-toluidine.hcl
c.i. 37085
nsc7629
devol red k
devol red ta salt
fast red salt tra
fast red salt tr
devol red tr
nsc-7629
kromon green b
4-chloro-2-methylaniline hydrochloride
fast red 5ct salt
azoic diazo component 11 base
brentamine fast red tr salt
azanil red salt trd
4-chloro-2-methylbenzenamine hydrochloride
3165-93-3
c.i. azoic diazo component 11
4-chloro-o-toluidine hydrochloride
hindasol red tr salt
fast red tr salt
p-chloro-o-toluidine hydrochloride
red trs salt
neutrosel red trva
4-chloro-o-toluidine (nh2=1) hydrochloride
red salt ciba ix
red salt irga ix
amarthol fast red tr salt
4-chloro-6-methylaniline hydrochloride
5-chloro-2-aminotoluene hydrochloride
2-amino-5-chlorotoluene hydrochloride
azoene fast red tr salt
nci-c02368
natasol fast red tr salt
diazo fast red tr
4-chloro-o-toluidine (nh2=1)
daito red salt tr
fast red salt trn
2-methyl-4-chloroaniline hydrochloride
wln: zr dg b1 &gh
chlorhydrate de 4-chloroorthotoluidine
4-chloro-2-toluidine hydrochloride
ofna-perl salt rra
sanyo fast red salt tr
ci azoic diazo component 11
nsc 7629
o-toluidine, 4-chloro-, hydrochloride
un1579
chlorhydrate de 4-chloroorthotoluidine [french]
amarthol fast red tr
rcra waste number u049
asymmetric meta-chloro-ortho-toluidine hydrochloride
clorhidrato de 4-cloro-o-toluidine
rcra waste no. u049
ccris 153
benzenamine, 4-chloro-2-methyl-, hydrochloride
hsdb 6191
chlorhydrate de chloro-4 o-toluidine
einecs 221-627-8
4-chloro-o-toluidinium chloride
4-chloro-o-toluidine hydrochloride [un1579] [poison]
unii-1y82dn556p
1y82dn556p ,
benzenamine, 4-chloro-2-methyl-, hydrochloride (1:1)
4-chloro-o-toluidine hcl
cas-3165-93-3
NCGC00256591-01
tox21_302920
dtxcid20288
dtxsid0020288 ,
NCGC00258835-01
tox21_201283
FT-0618236
4-chloro-o-toluidine hydrochloride [hsdb]
SCHEMBL131186
2 -amino-5 -chlorotoluene hydrochloride
VKYZDCTWJGBFDW-UHFFFAOYSA-N
AKOS016846210
CHEMBL3182298
4-chloro-2-methylaniline hydrochloride, aldrichcpr
J-018507
Q27253163
4-chloro-2-methylaniline;hydrochloride
D89231
4-chloro-o-toluidinehydrochloride

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" 4-CloT was administered orally over 28 consecutive days (days 1-28), followed by a 28-day treatment-free (days 29-56), and a second dosing phase of 3 days (days 57-59)."( DNA Damage Response of 4-Chloro-Ortho-Toluidine in Various Rat Tissues.
Christen, F; Funk, J; Guérard, M; Marchand, C; Winter, M; Zeller, A, 2018)		0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLI family zinc finger 3Homo sapiens (human)Potency40.85620.000714.592883.7951AID1259392
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency53.60690.001022.650876.6163AID1224838; AID1224893
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency76.72090.003041.611522,387.1992AID1159552; AID1159553; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency22.97520.001530.607315,848.9004AID1259401
estrogen nuclear receptor alphaHomo sapiens (human)Potency4.36470.000229.305416,493.5996AID743069
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency21.87510.023723.228263.5986AID743223
aryl hydrocarbon receptorHomo sapiens (human)Potency29.70110.000723.06741,258.9301AID743085; AID743122
heat shock protein beta-1Homo sapiens (human)Potency60.49180.042027.378961.6448AID743210; AID743228
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (21)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (28.57)18.7374
1990's8 (38.10)18.2507
2000's4 (19.05)29.6817
2010's3 (14.29)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 16.32

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index16.32 (24.57)
Research Supply Index3.22 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (16.32)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (12.50%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other21 (87.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
benzoic acid
Benzoic Acid: A fungistatic compound that is widely used as a food preservative. It is conjugated to GLYCINE in the liver and excreted as hippuric acid.. benzoic acid : A compound comprising a benzene ring core carrying a carboxylic acid substituent.. aromatic carboxylic acid : Any carboxylic acid in which the carboxy group is directly bonded to an aromatic ring.		1.9710benzoic acidsalgal metabolite;
antimicrobial food preservative;
drug allergen;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 3.1.1.3 (triacylglycerol lipase) inhibitor;
human xenobiotic metabolite;
plant metabolite
thymidine
[no description available]		1.9610pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
metabolite;
mouse metabolite
3-chloro-2-methylaniline
3-chloro-2-methylaniline: structure given in first source; RN given refers to parent cpd		1.9710
2-naphthylamine
2-Naphthylamine: A naphthalene derivative with carcinogenic action.. 2-naphthylamine : A naphthylamine carrying the amino group at position 2.		1.9910naphthylaminecarcinogenic agent
4-biphenylamine
4-biphenylamine: used in detection of sulfates, & as a carcinogen in cancer research; RN given refers to parent cpd; structure. biphenyl-4-amine : An aminobiphenyl that is biphenyl substituted by an amino group at position 4.		1.9910aminobiphenylcarcinogenic agent
2-toluidine
2-toluidine: RN given refers to parent cpd. o-toluidine : An aminotoluene in which the amino substituent is ortho to the methyl group.		2.8940aminotoluenecarcinogenic agent
methylaniline
methylaniline: RN given refers to parent cpd. methylaniline : A substituted aniline carrying one or more methyl groups at unspecified positions.		1.9710methylaniline;
phenylalkylamine;
secondary amine
benzyl acetate
benzyl acetate : The acetate ester of benzyl alcohol.		2.0110acetate ester;
benzyl ester		metabolite
chlorphenamidine
Chlorphenamidine: An acaricide used against many organophosphate and carbamate resistant pests. It acts as an uncoupling agent and monoamine oxidase inhibitor.		3.2360
chlorine
Chlorine: An element with atomic symbol Cl, atomic number 17, and atomic weight 35, and member of the halogen family.		1.9710diatomic chlorine;
gas molecular entity		bleaching agent
2-chloro-4-acetotoluidine
[no description available]		1.9610
chlorodibromomethane
[no description available]		2.0110organochlorine compound
ConditionIndicatedRelationship StrengthStudiesTrials
Chromosome-Defective Micronuclei
[description not available]		02.1710
Benign Neoplasms
[description not available]		04.0830
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		04.0830
Bladder Cancer
[description not available]		03.9850
Cancer of Digestive System
[description not available]		01.9610
Diseases, Occupational
[description not available]		03.840
Respiratory Tract Neoplasms
New abnormal growth of tissue in the RESPIRATORY SYSTEM.		01.9610
Urinary Bladder Neoplasms
Tumors or cancer of the URINARY BLADDER.		03.9850
Digestive System Neoplasms
Tumors or cancer of the DIGESTIVE SYSTEM.		01.9610
Chromosomal Translocation
[description not available]		01.9610
Abnormalities, Autosome
[description not available]		02.3920
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.9210
Carcinoma, Papillary
A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)		01.9810
Carcinoma, Transitional Cell
A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.		02.3820
Carcinoma, Anaplastic
[description not available]		01.9710
Carcinoma, Intraepithelial
[description not available]		01.9710
Carcinoma
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.		01.9710
Carcinoma in Situ
A lesion with cytological characteristics associated with invasive carcinoma but the tumor cells are confined to the epithelium of origin, without invasion of the basement membrane.		01.9710
Experimental Neoplasms
[description not available]		01.9610